PTPRC and neoplasm: In such scenarios, the FACS-based enrichment of CD45-negative and CD45-positive cells into two separate fractions provides a flexible option to later mix tumor and immune cells at a desirable ratio in order to obtain an adequate concentration of cells (n ≥ 20,000) for scRNA-seq.